DAX19.323 +0,9%ESt504.789 +0,7%MSCIW3.766 +0,3%Dow44.297 +1,0%Nas19.004 +0,2%Bitcoin94.595 -0,4%Euro1,0417 -0,6%Öl75,28 +1,2%Gold2.709 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 MicroStrategy 722713 Tesla A1CX3T Rheinmetall 703000 EVOTEC 566480 Bayer BAY001 Siemens Energy ENER6Y Deutsche Telekom 555750 Volkswagen (VW) vz. 766403 Amazon 906866 Deutsche Bank 514000 NEL ASA A0B733 Mercedes-Benz Group (ex Daimler) 710000 Palantir A2QA4J Coinbase A2QP7J
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX geht deutlich fester ins Wochenende -- US-Börsen schließen höher -- Bitcoin knapp vor 100.000 US-Dollar -- Chef der US-Börsenaufsicht tritt ab -- RWE, Secunet, NEL im Fokus
Top News
So entwickeln sich Bitcoin, Litecoin & Co am Samstagvormittag am Kryptomarkt So entwickeln sich Bitcoin, Litecoin & Co am Samstagvormittag am Kryptomarkt
Trump 2.0: Das könnte jetzt auf Europas Banken zukommen Trump 2.0: Das könnte jetzt auf Europas Banken zukommen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Provention Bio Aktie

NeuKaufenVerkaufen
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Bei einem anderen Broker handelnSmartphone
Div. Rendite0,00%

WKNA2JRLW

ISINUS74374N1028

SymbolPRVB

Provention Bio Aktien News

DatumMeistgelesen
PR NewswireSHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Provention Bio, Inc. - PRVB
PR NewswireProvention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
PR NewswireProvention Bio Announces the Grant of Inducement Awards
PR NewswireProvention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
PR NewswireProvention Bio Announces Completion of $35 Million Equity Investment from Sanofi US
PR NewswireProvention Bio to Present at the SVB Securities Global Biopharma Conference
PR NewswireProvention Bio Announces the Grant of Inducement Awards
PR NewswireProvention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD®
PR NewswireProvention Bio Announces the Grant of Inducement Awards
PR NewswireProvention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors
PR NewswireProvention Bio Announces the Grant of Inducement Awards
PR NewswireTZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with ...
PR NewswireProvention Bio Announces the Grant of Inducement Awards
PR NewswireProvention Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
PR NewswireProvention Bio to Report Third Quarter 2022 Financial Results on November 3, 2022
PR NewswireProvention Bio Announces the Grant of Inducement Awards
PR NewswireProvention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals
PR NewswireProvention Bio Announces Senior Leadership Addition
PR NewswireProvention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
PR NewswireProvention Bio Announces the Grant of Inducement Awards
PR NewswireProvention Bio Announces $125 Million Term Loan Facility with Hercules Capital
PR NewswireProvention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
PR NewswireProvention Bio Announces the Grant of Inducement Awards
PR NewswireProvention Bio to Report Second Quarter 2022 Financial Results on August 4, 2022
PR NewswireProvention Bio Announces $60 Million Private Placement
PR NewswireProvention Bio Announces the Grant of Inducement Awards
PR NewswireProvention Bio Announces Extension of FDA User Fee Goal Date for Teplizumab to November 17, 2022
PR NewswireProvention Bio Announces the Grant of Inducement Awards
PR NewswireProvention Bio to Present at the Jefferies Global Healthcare Conference
PR NewswireProvention Bio Announces Update to Board of Directors
PR NewswireProvention Bio to Host a May 19, 2022 Virtual Investor Event Focused on the Potential Commercial Launch of Teplizumab Later This Year
PR NewswireProvention Bio Reports First Quarter 2022 Financial Results and Provides Business Update
PR NewswireProvention Bio Announces the Grant of Inducement Awards
PR NewswireProvention Bio to Report First Quarter 2022 Financial Results on May 5, 2022
PR NewswireProvention Bio Announces the Grant of Inducement Awards
PR NewswireProvention Bio Announces Positive Final Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
PR NewswireProvention Bio Announces the Grant of Inducement Awards
PR NewswireProvention Bio to Present at Two Upcoming Virtual Investor Conferences
PR NewswireProvention Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
PR NewswireProvention Bio Announces Biologics License Application (BLA) Resubmission for Teplizumab to Address Complete Response Letter (CRL)

Provention Bio News

Provention Bio News: auf dieser Seite finden Sie alle Provention Bio News und Nachrichten zur Provention Bio Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Provention Bio News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Provention Bio News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.